Original Article cholesterolemia but also for the primary and secondary prevention of CAD. In fact, intensive LDL-lowering treatment with statin has efficiently reduced coronary events and mortality 1, 2) . However, recent clinical trials suggest that residual risks remain for CAD during the statin treatment, irrespective of the potency of statin 3) . These findings stimulate enhanced interest in therapeutic target beyond the quantity of LDL-C.
Introduction
The plasma level of low-density lipoprotein cholesterol (LDL-C) is the most valuable predictor and modulator for coronary artery disease (CAD). Statin treatment is a principal strategy, not only for hyper- From January 2010 to May 2011, a total of 145 consecutive patients with CAD, who underwent elected PCI at Kobe University Hospital and satisfied inclusion criteria, were enrolled in this study. Within 6 -9 months after the PCI, the CAD patients underwent coronary angiography (CAG) for the onset of ischemic symptoms or as a follow-up re-examination. In the CAD group, 103 patients were taking statin (CAD/statin ); 42 CAD patients were not taking statin (CAD/statin ). Patients who had arrhythmia, valvular disease, or cardiomyopathy, but not CAD were enrolled in the control group (non-CAD, n 82). In the non-CAD group, 40 patients were receiving statin (non-CAD/statin ) and 42 patients were not (non-CAD/statin ).
Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy
In addition, CAD patients were classified by means of follow-up coronary angiography, according to the following definition: patients who showed restenosis in the original stented segment (in-stent restenosis, ISR group); patients with occurrence of other nontarget coronary atherosclerotic lesions (de novo lesion group); and patients with neither ISR nor de novo lesion (no lesion group). ISR and de novo lesions were defined as displaying luminal stenosis ≥ 75% and demonstrating ischemia in the perfusion area of narrowed coronary by stress myocardial scintigram. CAD patients, who had been treated with a bare-metal stent or a drug-eluting stent, received dual antiplatelet therapy with aspirin and clopidogrel or ticlopidine. The diagnosis of hypertension (HT), diabetes mellitus (DM), dyslipidemia (DL), and metabolic syndrome (MetS) was defined as described previously 13) . Exclusion criteria were emergency admission, heart failure (New York Heart Association functional class 4), cancer in the past 5 years, pulmonary hypertension, serum triglyceride level 400 mg/dL, kidney failure (serum creatinine concentration 2.0 mg/dL or hemodialysis), and active inflammation (serum C-reactive protein concentration 1 mg/dL).
Biochemical Analyses
Serum samples were collected after overnight fast on admission for follow-up CAG. There was no difference in the time period from the prior PCI to the blood sampling among the groups. The samples were stored at 80 until use; conventional biochemical analyses were performed using standard techniques. Serum concentration of remnant-like particle cholesterol (RLP-C), apoB48, and estimated glomerular filtration rate (eGFR) were analyzed as described previously 13) . Serum levels of campesterol and lathosterol were measured by SRL, Inc. (Tokyo, Japan). mately 30% of total cholesterol, and the remaining 70% is synthesized in the body, while the liver predominantly regulates the circulating cholesterol level. In catabolism, cholesterol is excreted into the bile, then re-absorbed in the intestine or excreted into feces. Statin is a strong inhibitor of cholesterol synthesis, and, as a compensatory action, cholesterol absorption is increased 4) ; such an effect seems to depend on the LDL-lowering potency of the statin 5) . Cholesterol absorption also serves as a regulator of the serum LDL-C level 6) . It has been reported that cholesterol absorption is associated with recurrent cardiovascular events 7) , and the beneficial effect of statin was attenuated in patients with increased cholesterol absorption [8] [9] [10] . In a recent study, the addition of ezetimibe, a selective inhibitor of cholesterol absorption, to statin, resulted in further reduction of cardiovascular events in patients with acute coronary syndrome 11) . Moreover, impaired cholesterol homeostasis, as expressed by low synthesis and high absorption marker concentrations, is a predictor of CAD as shown in the Framingham study 9) . Thus, the change in the relative balance of circulation cholesterol may affect the prognosis of CAD, irrespective of plasma LDL-C levels. Although it is difficult to discriminate between exogenous and endogenous cholesterol, measurement of serum markers for cholesterol absorption (campesterol or sitosterol) and synthesis (lathosterol or desmosterol) has enabled estimation of the relative predominance of circulation exogenous and endogenous cholesterol. On the other hand, it has recently become possible to measure apolipoprotein B48 (apoB48) concentration, which is present only in intestinally derived exogenous lipoproteins, such as chylomicron and chylomicron remnants 12) .
Aim
We aimed to investigate whether the serum markers for exogenous lipids affect and predict CAD progression after percutaneous coronary intervention (PCI).
Methods

Patients
This study was performed in accordance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Clinical Research, enforced by the Ministry of Health, Labour and Welfare of Japan, from July 31, 2008. The protocol was approved by the Institutional Review Board of Kobe University Graduate School of Medicine, Japan. All patients gave informed written consent before enrolment.
parison tests.
Results
Controlled Serum Lipid Profile but Enhanced Cholesterol Absorption in CAD/Statin Patients
Baseline characteristics and lipid profiles in terms of CAD and statin use are shown in Table 1 . The CAD groups, with or without statin use, showed a high prevalence of HT and DM compared with the non-CAD groups. The CAD patients were taking intensive LDL-lowering therapy for secondary prevention as recommended 14) . As a result, the CAD/statin patients had significantly lower total cholesterol (TC) and LDL-C than the non-CAD/statin patients. However, the HDL-C level was lower and apoB48 concentration was higher in CAD patients than in
Statistical Analysis
Values are expressed as mean SD or frequencies (%). Variables (triglycerides, RLP-C, apoB, apoB48 and fasting plasma glucose) with skewed distribution were normalized by natural logarithmic transformation and were analyzed as follows: t -test unpaired, Spearman test, and one-way ANOVA were used to compare continuous variables. Chi-square test was used to compare categorical values. Stepwise multivariate logistic regression analysis was used to determine the best independent predictor of coronary risk in patients with de novo lesion progression compared with those with ISR or no lesions, with the p value-to-enter set at 0.10. All statistical analyses were performed using Stata 13.1 software (Stata, Texas, USA). p 0.05 was considered statistically significant. We adjusted significance levels by Bonferroni correction in multiple com- Values (mean SD) or numbers (% in parentheses) are shown. BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RLP-C, remnant-like particle cholesterol; TC, total cholesterol. P-values were calculated using chi-square test for categorical values and t -test unpaired for continuous variables.
Based on analysis normalized by logarithmic transformation.
Fig. 1. Cholesterol absorption and synthesis markers in CAD patients with or without statin
During statin therapy, compared with the non-CAD patients, cholesterol absorption marker (campesterol/TC, a) was significantly increased in CAD patients. Cholesterol synthesis marker (lathosterol/TC, b) was decreased in the patients with statin therapy compared with the patients without statin, whereas in he statin ( ) group, it was still higher in patients with CAD than in those without CAD. The campesterol/lathosterol ratio (c) was higher in patients with CAD than in corresponding patients without CAD, with and without statin therapy. CAD, coronary artery disease and TC, total cholesterol. p values were calculated using t -test unpaired.
lathosterol ratio in CAD patients was higher than that in non-CAD patients both with and without statin therapy (Fig.1c) . Increases in campesterol/TC, campesterol/lathosterol ratio, and apoB48 concentration in CAD/statin patients suggested that the cholesterol absorption in these patients was enhanced during LDL-C lowering therapy with statin.
Cholesterol Absorption Marker and ApoB48 Concentration were Associated with Coronary Lesion Prognosis
We investigated the association between cholesterol absorption or synthesis markers and coronary lesion progression during statin treatment. In the statin-treated CAD patients (n 103), 15 patients showed ISR, 18 patients had de novo lesions, and 70 patients did not show either ISR or de novo lesions at the time of follow-up CAG. As shown in Table 2 , non-CAD patients with or without statin treatment. There were no differences in triglycerides and RLP-C between these groups, with or without statin.
As shown in Fig. 1 and Table 1 , the cholesterol absorption marker (campesterol/TC) in the CAD/ statin patients was significantly higher than in the non-CAD/statin (Fig.1a, right panel) , while the level was similar in patients without statin (Fig. 1a, left  panel) . Cholesterol synthesis marker (lathosterol/TC) in patients receiving statin therapy was markedly low compared with that in patients not receiving statin (statin group: 0.56 0.31 µg/mg vs. statin-group: 1.41 0.72 µg/mg, p 0.001) (Fig. 1b) . However, lathosterol/TC in CAD/satin was still higher than that in non-CAD/statin , despite inhibition of synthesis by statin (Fig.1b, right panel) . Thus, the increase of campesterol/TC was not inversely proportional to the decrease in cholesterol absorption. Campesterol/ there was no difference in the prevalence of HT, DM, DL and MetS. Serum levels of HDL-C, LDL-C, triglycerides, and RLP-C were similar among the three groups. Thus, these conventional risk markers or serum lipid profiles did not predict coronary lesion prognosis in the secondary prevention. By contrast, there were significant differences in serum concentration of apoB48 and cholesterol absorption marker; in de novo group, campesterol/TC was higher than those in no lesion-and ISR groups ( Fig. 2a and Table 2 ). The cholesterol synthesis marker was not different among the three groups ( Fig. 2b and Table 2 ). Accordingly, the campesterol/lathosterol ratio was significantly higher in the de novo group than in no lesionand ISR groups (Fig. 2c, Table 2 ) because of the enhanced cholesterol absorption. These results suggest that the high levels of campesterol/TC, campesterol/ lathosterol ratio together with apoB48 concentration may represent the increase in cholesterol absorption and intestinal chylomicron production in CAD patients with de novo coronary stenosis, not with ISR. However, there was no significant correlation between cholesterol absorption marker and apoB48 concentration, both in all subjects (R 0.174, p 0.49) and in the CAD/statin group (R 0.275, p 0.29).
Campesterol/TC and ApoB48 Concentration are Predictors for de novo Lesion Progression
To confirm the impact of cholesterol absorption or synthesis markers on the prognosis of CAD, we performed univariate and stepwise multivariate logistic regression analysis, adjusted classical risk factors (age, gender, HT, DM, current smoking, TC, HDL-C and LDL-C) 15) , in addition to campesterol/TC, campesterol/lathosterol ratio and apoB48 concentrations. These analyses were performed between patients with de novo lesion progression and no lesion or ISR ( Table  3) . Univariate analysis showed that campesterol/TC, campesterol/lathosterol ratio, and apoB48 concentration were significantly associated with de novo lesion progression compared with no lesion progression or ISR. Furthermore, stepwise multivariate analysis revealed that both campesterol/TC and apoB48 concentrations were significant risk factors for de novo lesion progression ( Table 3 ). These findings suggest that intestinal lipid absorption and intestinal chylomicron production are linked, and serve as predictive risk markers for de novo lesion progression in CAD patients during statin treatment. Cholesterol absorption marker (campesterol/TC, a) and campesterol/lathosterol ratio (c) was higher in CAD patients with de novo lesion progression after coronary intervention than in patients with in-stent restenosis (ISR) or no lesion. Cholesterol synthesis marker (lathosterol/TC, b) was similar in the three groups. Abbreviations similar to those in Fig. 1 . p values were calculated using one-way ANOVA in the three groups. We adjusted significance levels by Bonferroni correction in multiple comparison tests.
expression of intestinal cholesterol transporter, Niemann-Pick C1-like 1 protein (NPC1L1) is elevated in patients with DM 18) . The enhanced cholesterol absorption may contribute to the prevalence of CAD in these pathological states.
Possible Mechanisms Underlying the Impact of Cholesterol Absorption on Atherosclerosis
Recent clinical studies have shown that the enhanced absorption and reduced synthesis of cholesterol may be related to coronary plaque volume or vulnerability 19, 20) . In combination with the present study, we speculated that an increase in diet-derived exogenous cholesterol might be, at least in part, responsible for the residual risks during statin treatment. As for a plausible mechanism, enhanced cholesterol absorption may be associated with enhanced absorption of proatherosclerotic oxidized cholesterol or oxysterols, such as alpha epoxycholesterol [21] [22] [23] .
Variation of Cholesterol Absorption/Synthesis in Plasma Lipid Profile and Atherosclerosis
Increased dietary cholesterol intake may increase serum cholesterol in some individuals, while there may be no response in other subjects 24, 25) . However,
Discussion
Enhanced Cholesterol Absorption in CAD Patients Receiving Statin
The present study has demonstrated that the level of cholesterol absorption marker was significantly higher in CAD/statin patients with de novo lesion progression than in those with no lesion or with ISR, despite comparable control of serum LDL-C levels in these groups. The relative increase of absorption was likely attributable to the compensation of the inhibition of hepatic cholesterol synthesis by statin 4) . However, statin treatment did not increase campesterol/TC in non-CAD patients (Table 1 and Fig. 1a) , and the lathosterol/TC in CAD/statin group was still higher than that in the non-CAD/statin group (Fig. 1b) . The findings indicate that the increase of campesterol/ TC in the CAD/statin cannot be explained simply by the compensatory effect of statin. We speculate that CAD patients may have some predisposing factor(s) to increase cholesterol absorption. Previous studies have reported that cholesterol absorption is increased in patients with CAD 9) . Also, cholesterol absorption is increased in patients with type 2 DM 16) and renal insufficiency 17) . Lally et al. have reported that the Univariate and stepwise multivariate analyses were performed in the patients with de novo lesion progression (n 18) as compared to ISR (n 15) or no lesion (n 70), in CAD patients with statin treatment. Stepwise multivariate analysis adjusted for age, gender, hypertension, diabetes mellitus, current smoking, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, campesterol/TC, campesterol/lathosterol ratio and apolipoprotein B48. ApoB48, apolipoprotein B48; CI, confidence interval; OR, odds ratio. Other abbreviations as in Table 1 and 2. Based on analysis normalized by logarithmic transformation.
patients with acute coronary syndrome has recently been reported 20) , and is consistent with our present study. Third, the serum LDL-C level was incompletely controlled in some subjects of CAD/statin-group, which may have some potential influence on the CAD prognosis. Fourth, we could not include data for the type/doses of statin, other anti-hyperlipidemic drugs including ezetimibe, and anti-diabetic drugs, because of the limited sample number. The correlation between cholesterol absorption/synthesis and potency of statin, or the LDL-C change should be clarified. Further studies, including a large-scale prospective study, are required to establish the impact of cholesterol absorption in risk management for CAD.
Conclusions
During intensive lipid-lowering therapy with statins, increased cholesterol absorption and intestinal chylomicron synthesis were associated with the progression of de novo coronary lesions. The finding suggests that inhibition of exogenous cholesterol absorption and chylomicron synthesis could be a possible therapeutic target for the secondary prevention of CAD during statin treatment.
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This work was supported by Grants-In-Aid for Scientific Research from the Ministry of Education, increased cholesterol absorption can cause hypercholesterolemia 6) ; in such a population, this would represent a CAD risk. There is a known variation in the effect of ezetimibe 26) and the effect is a counterpart of that of statin 27) . As a result, patients with low cholesterol absorption are expected to respond better to statins and worse to ezetimibe, and vice versa 28) . Inactivating mutations of NPC1L1 have been reported to reduce plasma LDL-C levels and the prevalence of CAD 29) . On the other hand, a partial ileal bypass is known to improve plasma lipid profile and CAD prognosis 30) . Taken together, the dietary and/or pharmaceutical inhibition of cholesterol absorption may reduce CAD events during statin treatment, particularly in subjects with enhanced cholesterol absorption.
Significance of Other Diet-derived Lipids in Atherosclerosis
Findings from a number of studies suggest that other markers for exogenous lipids may play a role in the development of CAD. Increased level of chylomicron remnants in fasting and postprandial states is correlated to atherogenicity, and high apoB48 concentrations significantly impact accumulation of the MetS or CAD 12, 31, 32) . While most of the lipids in remnant lipoprotein are triglycerides, intestinal cholesterol absorption is another regulator of remnant lipoproteins, as is apoB production 33, 34) . Furthermore, PCSK9, which down-regulates LDL-receptor, reportedly produces and stabilizes intestinal apoB48 by microsomal triglyceride transfer protein 35) . Statin treatment activates SREBP2 and thereby upregulates PCSK9, which modulates expression of various transporter molecules controlling cholesterol absorption and excretion 36) . These effects may contribute to the increase of intestinal triglyceride-rich apoB48 containing particles. On the other hand, elaidic acid (trans 9-C18:1) can be used as a tracer for exogenous fatty acids because humans cannot synthesize it. The serum elaidic acid level is elevated in young patients with CAD 13) . Taken together, the lipid-and protein component in chylomicron remnants appear closely linked, and may affect the prognosis of CAD, irrespective of plasma LDL-C concentration.
Limitations
First, this study was cross-sectional, conducted at a single-center with a limited number of patients. The major result was confined to statin-treated CAD patients after PCI, but not the whole population, including statin-untreated CAD after PCI and non-CAD patients. Second, we did not include emergency cases of acute coronary syndrome or severe congestive heart failure. The impact of cholesterol absorption in
